MKI67 and cancer: We looked at the markers of the Ki-67 proliferation index, which is increasingly being used as a surrogate marker of anti-tumor efficacy in various cancers, to determine the primary endpoint because it could be affected after a short course of oral metformin therapy and previous study has shown that the Ki-67 expression was strong correlation with patient survival (Li et al., 2015).